Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CHRS
CHRS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CHRS News
Coherus Oncology Prices $50.1 Million Public Offering
2d ago
NASDAQ.COM
Applied Materials Reports Strong Q1 Results, Shares Surge
2d ago
Benzinga
Coherus Oncology Prices Public Offering at $1.75 per Share
3d ago
seekingalpha
Coherus Oncology Prices Public Offering at $1.75 per Share
3d ago
Newsfilter
Johnson & Johnson Partners with Coherus for Cancer Trial
Feb 04 2026
seekingalpha
Oncolytics Biotech Strengthens Leadership Amid Oncology Market Surge
Jan 27 2026
Newsfilter
Oncolytics Biotech Strengthens Leadership for Oncology Trials
Jan 27 2026
PRnewswire
Oppenheimer Initiates Coherus Oncology (CHRS) at Outperform with $10 Price Target
Jan 23 2026
seekingalpha
Biotech Stocks Surge: Coherus Up 9.09% in After-Hours Trading
Jan 23 2026
NASDAQ.COM
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
Jan 16 2026
PRnewswire
Oncolytics Biotech Advances Immunotherapy for Accelerated Approval in Oncology
Jan 12 2026
Newsfilter
Coherus Oncology Showcases Multiomic Biomarker Data for CHS-114, a Selective Anti-CCR8 Cytolytic Antibody, at SITC Conference
Nov 07 2025
Newsfilter
Coherus Oncology (CHRS) Posts Q3 Loss and Falls Short of Revenue Projections
Nov 07 2025
NASDAQ.COM
Coherus Oncology to Attend Upcoming Investor Conferences
Oct 23 2025
Newsfilter
Coherus Oncology to Present Poster at the 40th Annual SITC Meeting
Oct 03 2025
Newsfilter
Brinker International Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
Sep 04 2025
Benzinga
Show More News
